Abstract
Inhibition of plasma kallikrein (pKal) activity is a validated mechanism for prevention of HAE attacks. High potency and long duration of action are key drivers of prophylactic efficacy of pKal inhibitors but both attributes are not currently available in the same HAE treatment. We sought to generate a monoclonal antibody (mAb) pKal inhibitor with both high potency and long duration of action.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
